Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study

被引：0
|
作者：
Pasello, G. [1 ,2 ]
Lorenzi, M. [1 ,2 ]
Crivellaro, G. [3 ]
Capelletto, E. [4 ]
Buttice, S. [4 ]
Perrone, F. [5 ]
Tiseo, M. [5 ,6 ]
Scotti, V. [7 ]
Polo, V. [8 ]
Favaretto, A.
Montrone, M. [9 ]
Berardi, R. [10 ]
Zustovich, F. [11 ]
Toschi, L. [12 ]
Bearz, A. [13 ]
Milella, M. [14 ]
Frega, S.
Bonanno, L. [3 ]
Guarneri, V. [1 ,2 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[2] IOV Ist Oncol Veneto IRCCS, Padua, Italy
[3] IOV Ist Oncol Veneto IRCCS, Oncol 2, Padua, Italy
[4] Azienda Osped Univ San Luigi Gonzaga, Dept Oncol, Orbassano, Italy
[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[6] Univ Parma, Dept Med & Surg, Parma, Italy
[7] AOUC Azienda Osped Univ Careggi, Dipartimento Oncol, Florence, Italy
[8] Osped Reg Ca Foncello, AULSS2 Dept Med Specialist, Treviso, Italy
[9] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Dipartimento Area Med, Bari, Italy
[10] AOU Osped Riuniti Umberto 1 GM Lancisi G Salesi, Dept Internal Med, Clin Oncol, Torrette Di Ancona, Italy
[11] Osped Belluno, Belluno, Italy
[12] Ist Clin Humanitas, Med Oncol Dept, Rozzano, Italy
[13] Ctr Riferimento Oncol CRO, Med Oncol, Aviano, Italy
[14] Univ Verona, Med Oncol 1, Fac Med, Verona, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21P
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [41] A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors
    Lin, Lin
    Pan, Hongming
    Li, Xingya
    Zhao, Chengling
    Sun, Jiangtao
    Hu, Xingsheng
    Zhang, Yiping
    Wang, Mengzhao
    Ren, Xiubao
    Luo, Xiaoyong
    Shan, Guoyong
    Hui, Ai-Min
    Wu, Zhuli
    Liu, Huilong
    Tian, Ling
    Shi, Yuankai
    LUNG CANCER, 2022, 166 : 98 - 106
  • [42] FREQUENT BASELINE EGFR MUTATION T790M IN CYTOLOGICAL SPECIMENS OF TYROSINE KINASE INHIBITOR (TKI) NAIVE ADENOCARCINOMA NSCLC PATIENTS
    Andarini, S. L.
    Zaini, J.
    Hudoyo, A.
    Hidayat, H.
    Widjajahakim, G.
    Utomo, A. R.
    RESPIROLOGY, 2016, 21 : 79 - 79
  • [43] Survival outcome and cost-effectiveness of tyrosine kinase inhibitor in EGFR sensitive mutation advanced-stage NSCLC in Thammasat university hospital
    Rungtivasuwan, C.
    Eiamprapaporn, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1589 - S1589
  • [44] Combination Therapy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel for Metastatic Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Resistance and EGFR Mutations
    Kobayashi, Hironori
    Otsuki, Ayumu
    Ikeda, Sadakatsu
    Nakashima, Kei
    Oyama, Yu
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [45] Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses
    Halmos, Balazs
    Pennell, Nathan A.
    Otterson, Gregory Alan
    Gadgeel, Shirish M.
    Mekhail, Tarek
    Snell, Michael Robert
    Kuebler, J. Phillip
    Fu, Pingfu
    Sharma, Neelesh
    Dowlati, Afshin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Monitoring EGFR T790M with plasma DNA in lung cancer patients treated with EGFR tyrosine kinase inhibitor in prospective observational study.
    Sueoka-Aragane, Naoko
    Katakami, Nobuyuki
    Satouchi, Miyako
    Yokota, Soichiro
    Aoe, Keisuke
    Iwanaga, Kentaro
    Otsuka, Kojiro
    Kimura, Shinya
    Negoro, Shunichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    LABORATORY INVESTIGATION, 2010, 90 : 397A - 397A
  • [48] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    MODERN PATHOLOGY, 2010, 23 : 397A - 397A
  • [49] Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
    Zhong, Hua
    Zhang, Xueyan
    Tian, Panwen
    Chu, Tianqing
    Guo, Qisen
    Yu, Xinmin
    Yu, Zhuang
    Li, Yalun
    Chen, Lijuan
    Liu, Jie
    Zhang, Yan
    Guan, Yan
    Shi, Xun
    Wang, Jing
    Zhao, Yanqiu
    Han, Baohui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (08)
  • [50] Role of late response evaluation in Non Small Cell Lung Cancer (NSCLC) treated with EGFR Tyrosine Kinase Inhibitor with PET quantitative parameters
    Bhoil, A.
    Mittal, B.
    Singh, N.
    Singh, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S307 - S308
12345